MyFinsight
Home
Blog
About
Contact
Download
Download image
Total comprehensive
loss for the year, net...
-$43,934K
Unrealized gain on
available-for-sale securities, net...
$4K
Loss for the year
-$43,938K
Loss before tax
-$43,938K
Foreign exchange
gains/(losses)
$4,279K
Fair value change -
warrants
-$339K
Fair value change -
earnout
-$998K
Interest income
$6,960K
Supply revenue
$95K
License revenue
attributed from r&d...
$5,531K
Operating loss
-$56,847K
Revenue
$7,385K
Total operating
expenses
$64,232K
Selling, general and
administrative expenses
$27,278K
Research and development
expenses
$36,954K
Back
Back
Income Statement
source: myfinsight.com
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)